Advances in hidradenitis suppurativa
Transcript: What was the most important piece of new research presented at EADV 2024?
Martina Porter
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
This was my first time ever attending EADV because I'm American, and I've always only attended our American Academy of Dermatology, but I was really excited to see the number of presentations and I think the kind of variable presentations too because there are a bunch on therapeutics and then also a lot of presentations on comorbidities.
But the ones that I saw that I think were most interesting or impactful were, [redacted] showed bimekizumab's long-term or two-year extension data from their phase 3 trials and really showed a durable response over time for patients, which I think is very exciting cause we don't have that much data yet on how well patients do on biologic therapy over many years. And then also I presented our late-breaking abstract for [redacted] topical ruxolitinib cream for the 32-week data. And I think that is actually quite exciting for patients too because they found in the 32-week period that the patients had been in a double-blind, placebo-controlled period for 16 weeks.
And there was a difference between the topical ruxolitinib and the placebo, but the patients in the placebo crossed over and at 32 weeks had very similar responses to patients who were treated for the first 16 weeks with a drug. And so I think it's just very exciting to see that we have so many new therapies coming out for HS and that are in the pipeline.
And I expect that we'll continue to see a lot more because there are quite a few companies doing clinical trials in this space. And it's just a really wonderful thing for patients to have so many different options.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently of the sponsor, UCB Biopharma SRL, which has had no editorial input into the content. EPG Health received funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.